<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276625</url>
  </required_header>
  <id_info>
    <org_study_id>R5</org_study_id>
    <nct_id>NCT02276625</nct_id>
  </id_info>
  <brief_title>One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding</brief_title>
  <official_title>One-visit Multi-site Pre-exposure Intradermal Rabies Vaccination: Dose Finding in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine optimum dose level for a single visit multidose intradermal injection of rabies
      vaccine with the aim to induce immunological memory in all subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Memory response in vaccinated subjects 1 year after primary vaccination (defined as seroprotection rate for all subjects within 7 days post-booster in a simulated post-exposure scenario)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rabies Pre-exposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>A - ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal administration. 20% dose in a single visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal administration. 40% dose in a single visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal administration. 60% dose in a single visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1x IM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rabies vaccine</intervention_name>
    <description>Compare ID administration to IM administration. 1 visit schedule.</description>
    <arm_group_label>A - ID</arm_group_label>
    <arm_group_label>B - ID</arm_group_label>
    <arm_group_label>C - ID</arm_group_label>
    <arm_group_label>D - IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Good health according to the investigator

          -  Willingness and ability to adhere to the study regimen

          -  Able to give informed consent

        Exclusion Criteria:

          -  Known or suspected previous vaccination against rabies

          -  Known or suspected allergy against any of the vaccine components

          -  History of unusual or severe reactions to any previous vaccination

          -  Immunocompromized state due to illness or medication

          -  Administration of plasma or blood products three months prior to inclusion in the
             study

          -  (hydroxy)chloroquine or mefloquine use

          -  History of any neurological disorder including epilepsy or febrile seizures

          -  Pregnancy or breastfeeding

          -  Any current infectious disease other than seasonal cold

          -  Bleeding disorders or use of anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Visser, M, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emile Jonker, MD</last_name>
    <email>e.f.f.jonker@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>South-Holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Visser, MD, PhD</last_name>
      <email>l.g.visser@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Emile Jonker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leo Visser, Professor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

